These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15023364)

  • 1. Inhibition of Hsp90: a new strategy for inhibiting protein kinases.
    Sreedhar AS; Soti C; Csermely P
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):233-42. PubMed ID: 15023364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure, function and regulation of the hsp90 machinery.
    Li J; Buchner J
    Biomed J; 2013; 36(3):106-17. PubMed ID: 23806880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90: chaperoning signal transduction.
    Richter K; Buchner J
    J Cell Physiol; 2001 Sep; 188(3):281-90. PubMed ID: 11473354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS; Kerr TD
    Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hsp90--a target for anticancer therapy].
    Růcková E; Müller P; Vojtesek B
    Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular chaperones and protein kinase quality control.
    Caplan AJ; Mandal AK; Theodoraki MA
    Trends Cell Biol; 2007 Feb; 17(2):87-92. PubMed ID: 17184992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HSP90 molecular chaperones: moving into the clinic.
    Garcia-Carbonero R; Carnero A; Paz-Ares L
    Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibitors as therapy for multiple myeloma.
    Usmani SZ; Chiosis G
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S77-81. PubMed ID: 22035754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hsp90 molecular chaperone: an open and shut case for treatment.
    Pearl LH; Prodromou C; Workman P
    Biochem J; 2008 Mar; 410(3):439-53. PubMed ID: 18290764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
    Barbagallo I; Parenti R; Zappalà A; Vanella L; Tibullo D; Pepe F; Onni T; Li Volti G
    Acta Histochem; 2015 Oct; 117(8):705-11. PubMed ID: 26493719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.
    Petrikaitė V; Matulis D
    Medicina (Kaunas); 2011; 47(8):413-20. PubMed ID: 22123555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.